Table 4.

Genes that have a cohort-dependent association (P-value < 0.05) with the lifetime glioblastoma survival

Gene Symbol	Probe Identifier	Clinical Cohort	P-value	Level of Clinical Cohort	Hazard Ratio1	Relevant literature references
Prkcb2	207957_s_at	Gender	<.0001	Male	0.36 (0.24-0.55)	[28]G
				Female	1.27 (0.84-1.93)
		Therapy	0.0006	None	0.38 (0.25-0.60)
				CRnoT	0.51 (0.36-0.73)
				R	0.64 (0.46-0.88)
				CRT	0.71 (0.44-1.13)
				Other	0.75 (0.43-1.32)
Sox10	209843_s_at	Race	0.0018	White	0.55 (0.44-0.68)	[10]G
				Other	1.08 (0.72-1.62)
Egfr	211607_x_at	Gender	<.0001	Male	0.60 (0.50-0.72)	[24]G
				Female	0.88 (0.74-1.04)
Chi3l1	209396_s_at	Therapy	0.0006	CRT	1.27 (0.96-1.70)	[70]G
				R	1.28 (1.07-1.52)
				Other	1.31 (1.04-1.66)
				CRnoT	1.53 (1.31-1.79)
				None	2.42 (1.56-3.75)
C2	203052_at	Gender	0.0033	Female	1.30 (1.03-1.65)	n/a
				Male	1.93 (1.56-2.39)
Prkcb	209685_s_at	Gender	<.0001	Female	1.31 (0.79-2.14)	[28]G
				Male	5.21 (3.16-8.61)

n/a, No association with any type of cancer found in literature;

¹ Hazard ratio estimate (95% confidence interval);

² Interaction with a single clinical cohort factor;

^G Gene confirmed in an independent glioblastoma multiforme study; the number between square brackets denotes the corresponding literature reference;

^O Gene confirmed in an independent study on any other type of cancer; the number between square brackets denotes the corresponding literature reference.